Abstracts tagged "Spondylarthritis and tumor necrosis factor (TNF)"

Abstract Number: 276 • 2018 ACR/ARHP Annual Meeting
Gender Differences in TNFi Treatment Adherence and Response in As Patients: A Prospective Longitudinal Cohort Study
S. Hoekstra¹, Tamara Rusman², Michael T. Nurmohamed³, Christiaan van Denderen⁴ and Irene van der Horst-Bruinsma⁵, ¹Rheumatology, VU Univeresity Medical Center, Amsterdam, Netherlands, ²Rheumatology, VU University medical centre, Amsterdam, Netherlands, ³Rheumatology, Amsterdam Rheumatology and immunology Center, VU University Medical Center, Amsterdam, Netherlands, ⁴Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁵Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Despite several observations of gender differences in TNF inhibitor (TNFi) treatment response and adherence in ankylosing spondylitis (AS) patients, limited studies were conducted. Our…
Abstract Number: 2598 • 2018 ACR/ARHP Annual Meeting
Efficacy of Anti-Tumor Necrosis Factor (TNF) Alpha Therapy, in Patients with Spondylarthritis in the University Center of Rouen in France, Divived to the Berlin Algorithm Modified By the Assessement Spondylarthritis Group: A Ten Years Retrospective Study
Christelle Princivil¹, thierry Lequerre², Didier Alcaix³ and Olivier Vittecoq⁴, ¹Jacques Monod hospital center, 76290 Montivilliers, France, montivilliers, France, ²Rheumatology Department, Rouen University Hospital, University of Rouen, 76031 Rouen, France., ROUEN, France, ³Rheumatology Department, Jacques Monod Hospital Center, 76290 Montivilliers, France, montivilliers, France, ⁴INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France
Background/Purpose: Treatments and diagnosis of SpA is a public health problem. The efficacy of anti-TNF alpha treatment is different from one patient to an other.…
Abstract Number: 1547 • 2017 ACR/ARHP Annual Meeting
Dose Tapering of TNFi in Patients with Axial Spondyloarthritis: An Observational Cohort Study from Nationwide Korean College of Rheumatology Biologic Registry (KOBIO)
Jun Won Park¹, Jin Kyun Park¹, Kichul Shin², Yong-Beom Park³, Eun Bong Lee¹, Yeong Wook Song⁴ and Eun Young Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ²Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South), ³Yonsei University Severance Hospital, Seoul, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)
Background/Purpose: To compare the clinical efficacy of dose-tapering strategy of tumor-necrosis factor inhibitor (TNFi) with that of standard-dose TNFi treatment in patients with spondyloarthritis (SpA)…
Abstract Number: 2463 • 2017 ACR/ARHP Annual Meeting
Golimumab in Biologic-NaïVe Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Subanalysis from a Non-Interventional Evaluation in Germany
Klaus Krüger¹, Gerd R. Burmester², Siegfried Wassenberg³, Martin Bohl-Buehler⁴ and Matthias H. Thomas⁵, ¹Praxiszentrum St. Bonifatius München, München, Germany, ²Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ³Rheumazentrum Ratingen, Ratingen, Germany, ⁴Friedrich-Ebert-Str. 35, Rheumahaus, Potsdam, Germany, ⁵Medical Affairs, MSD Sharp & Dohme GmbH, Bünde, Germany
Background/Purpose: Golimumab (GLM) has demonstrated efficacy and safety in several randomized clinical trials with biologic-naïve patients (pts.). However, more data regarding the effectiveness and patient-reported…
Abstract Number: 2481 • 2017 ACR/ARHP Annual Meeting
Long-Term Safety of Adalimumab (HUMIRA) in Adult Patients from Global Clinical Trials across Multiple Indications: An Updated Analysis in 29,987 Patients Representing 56,951 Patient-Years
Gerd R. Burmester¹, Remo Panaccione², Kenneth B. Gordon³, James T. Rosenbaum⁴, Dilek Arikan⁵, Winnie L. Lau⁵ and Rita Tarzynski-Potempa⁵, ¹Charité - University Medicine Berlin, Berlin, Germany, ²University of Calgary, Calgary, AB, Canada, ³Medical College of Wisconsin, Milwaukee, WI, ⁴Ophthalmology, Oregon Health & Science University and Legacy Devers Eye Institute, Portland, OR, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: Adalimumab is an anti–tumor necrosis factor-α (TNF-α) agent indicated for the treatment of immune-mediated diseases. The long-term safety of adalimumab was previously reported in…
Abstract Number: 2725 • 2016 ACR/ARHP Annual Meeting
Elevated Disease Activity in Disease-Related Spondyloarthritis Despite Use of Tumor Necrosis Factor Inhibitor Therapies
Delamo Bekele¹, Ryan Duong², Patrick R. Wood³, Mena Hashim⁴, Jason Hou⁵, Jessica Walsh⁶, Maureen Dubreuil^7,8, Daniel Clegg⁹, Prashant Kaushik¹⁰, Bernard Ng^11,12, Elizabeth Chang¹³, Andreas M. Reimold¹⁴, Liron Caplan¹⁵ and Gail S. Kerr¹⁶, ¹Medicine, Howard University Hospital, Washington, DC, ²Rheumatology, Denver Veterans Affairs Medical Center and UC Denver SOM, Denver, CO, ³Internal Medicine, University of Colorado School of Medicine, Aurora, CO, ⁴Denver VAMC, Denver, CO, ⁵Gastroenterology, Houston VAMC and Baylor College of Medicine, Houston, TX, ⁶Division of Rheumatology, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ⁷Rheumatology, Boston VA HealthCare System, Boston, MA, ⁸Rheumatology, Boston University Medical Center, Boston, MA, ⁹Rheumatology, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ¹⁰Rheumatology/Medicine, Stratton VAMC, Albany, NY, ¹¹Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, ¹²Rheumatology, VA Puget Sound Healthcare System, Seattle, WA, ¹³Rheumatology, Veterans Affairs, Phoenix, AZ, ¹⁴Rheumatology, VAMC and University of Texas Southwestern, Dallas, TX, ¹⁵Div of Rheumatology, Denver VA and University of Colorado School of Medicine, Aurora, CO, ¹⁶Washington DC VAMC, Georgetown University Hospital, Howard University Hospital, Washington, DC
Background/Purpose: Spondyloarthritis (SpA) includes a wide range of overlapping diseases for which there are a limited number of approved pharmacologic agents that have been…
Abstract Number: 1916 • 2014 ACR/ARHP Annual Meeting
Stromal Overexpression of Transmembrane TNF Induces Spa-like Arthritis and Spondylitis in Mice
Leonie M. van Duivenvoorde^1,2, Melissa N. van Tok³ and Dominique L. Baeten^1,4, ¹Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ²Experimental Immunology, Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ³Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ⁴Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: The immunopathology of spondyloarthritis (SpA) is determined by inflammation and structural damage, in particular osteoproliferation, of axial and peripheral joints. The failure of TNF…
Abstract Number: 2467 • 2013 ACR/ARHP Annual Meeting
Response to Tumor Necrosis Factor inhibitors In Axial Spondyloarthritis: Does Sacroiliitis Make Any Difference?
Julien Girodon¹, Vianney Jouhet² and Elisabeth Solau-Gervais¹, ¹Rheumatology, University Hospital of Poitiers, Poitiers, France, ²Informatic, University hospital Bordeaux, Bordeaux, France
Background/Purpose: Axial spondyloarthritis (SpA) are characterized by sacroiliitis. The TNF inhibitors (TNFi) have been proven to be highly effective in ankylosing spondylitis. Recently, adalimumab demonstrate…
Abstract Number: 536 • 2013 ACR/ARHP Annual Meeting
Membrane-Bound TNF Drives Axial and Peripheral Inflammation and Pathologic New Bone Formation
Leonie M. van Duivenvoorde¹, Melissa N. van Tok¹ and Dominique L. Baeten², ¹Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ²Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: The morbidity of spondyloarthritis (SpA) is determined not only by inflammation but also by structural damage, in particular osteoproliferation leading to joint ankylosis. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].